emerg
pathogen
either
new
newli
recogn
increas
incid
spread
sinc
ident
emerg
pathogen
anim
reservoir
difficult
predict
develop
pathogenspecif
therapeut
vaccin
problemat
highli
pathogen
sar
coronaviru
sarscov
emerg
zoonot
pool
caus
global
epidem
sever
acut
respiratori
syndrom
sar
mani
patient
sarscov
experienc
exacerb
form
diseas
call
acut
respiratori
distress
syndrom
ard
requir
mechan
ventil
supplement
oxygen
half
patient
die
similar
viral
pathogen
like
influenza
west
nile
viru
sever
sarscov
diseas
increas
age
unfortun
success
vaccin
vulner
popul
difficult
task
immunolog
defici
associ
age
immun
senesc
due
rapid
viru
emerg
technolog
like
synthet
biolog
har
facilit
rapid
recombin
viru
construct
studi
novel
viru
biolog
pathogenesi
evalu
therapeut
intervent
sinc
predict
antigen
ident
futur
emerg
difficult
candid
vaccin
therapeut
maxim
breadth
crossprotect
panel
antigen
diverg
synthet
reconstruct
virus
use
tool
evalu
discuss
synthet
reconstruct
mani
anim
human
sarscov
provid
model
studi
molecular
mechan
govern
emerg
pathogenesi
viral
diseas
addit
review
evolut
epidemiolog
pathogenesi
epidem
zoonot
sarscov
focu
develop
broadli
reactiv
therapeut
vaccin
protect
age
popul
zoonot
pool
mani
diseas
great
human
histor
signific
ancient
recent
past
like
plagu
smallpox
hiv
influenza
emerg
wild
domest
anim
popul
caus
devast
human
diseas
achtman
et
al
li
et
al
nguyen
et
al
parrish
kawaoka
tumpey
et
al
wolf
et
al
woo
et
al
novel
coronaviru
sarscov
emerg
suddenli
caus
agent
sever
acut
respiratori
syndrom
sar
spread
worldwid
caus
case
death
christian
et
al
ksiazek
et
al
rota
et
al
virus
similar
epidem
strain
isol
civet
sale
within
wet
market
china
epidem
reemerg
chines
guan
et
al
genom
sequenc
virus
isol
bat
civet
human
suggest
virus
circul
bat
cross
speci
barrier
infect
civet
serv
amplif
host
yet
anoth
hostrang
shift
gener
human
tropic
viru
chines
guan
et
al
lau
et
al
li
et
al
sinc
virus
similar
epidem
strain
sarscov
current
circul
zoonot
pool
futur
emerg
sarscovlik
viru
may
occur
occur
ebola
influenza
marburg
chikungunya
viru
kaur
et
al
leroy
et
al
towner
et
al
woo
et
al
therefor
imper
understand
pathogen
mechan
coronaviru
lung
diseas
current
vaccin
passiv
serotherapi
effect
protect
human
infect
zoonot
sarscov
though
consider
amount
work
enhanc
knowledg
sarscov
pathogenesi
therapeut
treatment
design
mani
question
remain
unansw
host
factor
contribut
protect
prevent
sever
diseas
sarscov
therapeut
effect
futur
emerg
ration
design
antivir
therapi
futur
emerg
unknown
antigen
ident
sarscov
therapeut
protect
vulner
human
popul
current
research
aim
answer
question
focu
review
sarscov
thought
emerg
suddenli
zoonot
pool
viru
molecular
epidemiolog
suggest
epidem
strain
evolv
batassoci
sarscovlik
virus
way
intermedi
civet
host
fig
without
sarscov
evolut
promot
effici
infect
human
cell
persontoperson
transmiss
emerg
sarscov
epidem
would
occur
thu
zoonot
sarscov
adapt
necessari
initi
step
sarscov
human
pathogenesi
sequenc
analysi
zoonot
earli
middl
latestag
epidem
strain
coupl
vitro
evolut
experiment
demonstr
zoonot
isol
rapidli
adapt
effici
growth
human
airway
cell
multipl
genet
pathway
chines
guan
et
al
li
et
al
li
et
al
sheahan
et
al
sheahan
et
al
plastic
sarscov
spike
glycoprotein
receptor
interact
particularli
troubl
harbing
eas
potenti
futur
crossspeci
transmiss
sarscov
thought
transmit
direct
patient
contact
airborn
droplet
nuclei
contact
fomit
urinefec
contact
mucou
membran
peiri
et
al
peiri
et
al
brief
incub
period
approxim
day
patient
enter
acut
phase
infect
character
fever
f
chill
malais
myalgia
booth
et
al
liang
et
al
peiri
et
al
acut
phase
infect
patient
develop
nonproduct
coughshort
breath
dyspnea
bilater
pulmonari
infiltr
seen
chest
radiographi
pulmonari
lesion
visibl
radiographi
continu
worsen
day
onset
symptom
ao
patient
begin
improv
approxim
patient
show
clinic
improv
first
week
ill
remain
present
recur
fever
short
breath
peiri
et
al
peiri
et
al
case
studi
health
care
worker
toronto
n
age
mean
year
age
rang
year
provid
typic
exampl
cours
sarscov
convalesc
week
hospit
discharg
patient
complain
dyspnea
weak
lethargi
suffer
signific
weight
loss
anorexia
sarscov
diseas
three
week
discharg
toronto
healthcar
worker
cohort
longer
weak
continu
gain
weight
still
suffer
dyspnea
patient
fig
schemat
sarscov
emerg
zoonot
pool
virus
similar
epidem
strain
sarscov
sar
urbani
found
within
chines
horsesho
bat
believ
anim
reservoir
sarscov
like
virus
within
live
anim
market
china
postul
interact
bat
himalayan
palm
civet
help
viru
jump
speci
infect
civet
virus
close
relat
sar
urbani
found
civet
market
epidem
time
civet
virus
transmit
human
ultim
result
viru
could
transmit
person
person
earli
middl
late
phase
epidem
sarscov
evolv
viru
stabil
sar
urbani
still
present
abnorm
chest
xray
patient
case
studi
hong
kong
provid
detail
exampl
nonconvalesc
cohort
lung
damag
continu
progress
minor
patient
diffus
ground
glass
chang
seen
chest
xray
typic
acut
lung
injuri
ali
acut
respiratori
distress
syndrom
ard
peiri
et
al
ali
progress
ard
character
primarili
acut
onset
bilater
infiltr
chest
radiograph
hypoxemia
fever
leukopenia
bauer
et
al
ali
ard
inflammatori
lung
diseas
character
diffus
alveolar
infiltr
hypoxia
respiratori
failur
death
due
failur
multipl
organ
sever
form
ali
ard
fatal
almost
patient
peopleyear
worldwid
rank
among
difficult
challeng
criticalcar
medicin
kuba
et
al
ard
character
diffus
alveolar
damag
dad
includ
proteinrich
edema
exud
phase
hyalin
membran
inflamm
lead
surfact
dysfunct
sever
hypoxia
neutrophil
domin
bronchoalveolar
lavag
bal
fluid
cytokin
tnfa
often
elev
bauer
et
al
dahlem
et
al
guidot
et
al
exud
phase
last
week
progress
prolif
phase
progress
organ
result
fibrosi
fibrot
phase
approxim
sar
patient
requir
intens
care
unit
icu
treatment
due
ard
symptom
major
admit
icu
requir
mechan
ventil
oxygen
support
booth
et
al
peiri
et
al
though
overal
mortal
rate
global
sarscov
epidem
approach
mortal
rate
patient
age
rang
approxim
result
comorbid
immun
senesc
booth
et
al
leung
et
al
liang
et
al
peiri
et
al
lung
primari
target
cell
sarscov
infect
human
remain
controversi
sever
thorough
patholog
studi
postmortem
tissu
sarscov
infect
identifi
ciliat
epitheli
cell
type
ii
pneumocyt
within
lung
primari
target
viru
infect
though
viru
antigen
also
found
macrophag
dendrit
cell
dc
cell
b
cell
nk
cell
put
lung
stemprogenitor
cell
chen
et
al
gu
et
al
hwang
et
al
nichol
et
al
tse
et
al
ye
et
al
unfortun
insitu
hybrid
util
patholog
studi
unabl
differenti
activ
viral
infect
uptak
viru
passiv
cellular
mean
like
phagocytosi
sever
vitro
studi
demonstr
human
dc
unabl
support
activ
viru
replic
instead
instig
cell
activ
lead
upregul
mhc
ii
secret
inflammatori
cytokin
law
et
al
tseng
et
al
support
gross
lung
patholog
seen
xray
microscop
evalu
sarscov
lung
patholog
repeatedli
describ
variou
cohort
show
variou
phase
exud
prolif
acut
lung
injuri
ali
gu
et
al
hwang
et
al
nichol
et
al
tse
et
al
typic
sarscov
lung
patholog
character
inflammatori
cell
infiltr
pulmonari
edema
hyalin
membran
format
mild
moder
fibrosi
alveolar
epitheli
hyperplasia
alveolarepitheli
cell
desquamin
ie
slough
gu
et
al
hwang
et
al
tse
et
al
two
postdischarg
cohort
percentag
patient
continu
symptom
pulmonari
fibrosi
rang
develop
fibrosi
associ
increas
age
admiss
intens
care
antonio
et
al
wang
et
al
pulmonari
fibrosi
pf
devast
diseas
almost
univers
fatal
outcom
character
inflamm
alveoli
damag
lung
tissu
progress
interstiti
fibrosi
harden
tissu
five
million
peopl
worldwid
affect
pf
includ
case
culmin
deathsyear
us
http
wwwpulmonaryfibrosisorghomehtm
model
virusinduc
pf
essenti
understand
manag
devast
endstag
clinic
diseas
ultim
clinic
cours
ard
often
determin
abil
injur
lung
repopul
alveolar
epithelium
function
cell
death
may
occur
fibrosi
predomin
heal
respons
worsen
lung
complianc
oxygen
chest
xray
serolog
virolog
data
suggest
direct
involv
adapt
immun
respons
viral
clearanc
detail
virologicalimmunolog
longitudin
analysi
perform
cohort
sar
patient
hong
kong
peiri
et
al
five
day
ao
nasopharyng
aspir
contain
log
genomesml
sarscov
day
rang
tighten
log
genomesml
patient
sarscovspecif
igg
seroconvers
begin
near
day
ao
mean
day
ao
viru
titer
begin
fall
interestingli
cohort
n
seroconvert
day
ao
seroconvert
day
ao
even
seroconvers
viral
genom
detect
nasopharyng
aspir
stool
urin
far
day
ao
note
mani
patient
hong
kong
cohort
treat
corticosteroid
drug
may
delay
onset
seroconvers
anim
model
coronaviru
lung
infect
prcv
similar
patholog
sarscov
administr
corticosteroid
allevi
sign
prcv
pneumonia
earli
dpi
though
exacerb
later
stage
diseas
dpi
probabl
due
lack
cellmedi
respons
creat
environ
extend
viru
lung
replic
jung
et
al
togeth
data
suggest
administr
corticosteroid
sarscov
acut
infect
may
exacerb
diseas
due
dampen
cellmedi
immun
respons
anoth
hong
kong
sar
cohort
seroconvers
detect
earli
day
ao
median
seroconvers
occur
day
ao
lee
et
al
lastli
cameron
et
al
correl
elev
level
antisarscov
sspecif
antibodi
patient
sera
lesssever
diseas
nevertheless
data
suggest
adapt
immun
respons
mount
viral
load
depress
pave
way
convalesc
unfortun
current
anim
model
fail
recapitul
adapt
immun
respons
sarscov
import
insight
mechan
innat
inflammatori
respons
sarscov
infect
glean
sever
clinic
vitro
vivo
anim
model
studi
yet
clear
concis
model
innat
respons
relat
viral
pathogenesi
remain
elucid
inconsist
experiment
protocol
clinic
treatment
cell
type
infect
vitro
possibl
speciesspecif
effect
within
variou
anim
model
creat
confus
complic
bodi
data
make
gener
comprehens
model
sarscov
pathogenesi
difficult
nevertheless
concord
data
experiment
system
provid
coronaviru
field
great
bodi
use
inform
data
summar
thorough
evalu
inflammatori
gene
express
sarscov
patient
peripher
blood
mononuclear
cell
pbmc
perform
cameron
et
al
regunathan
et
al
investig
arriv
dispar
conclus
cameron
et
al
conclud
robust
type
inf
respons
observ
earli
progress
diseas
predict
essenti
viral
clearanc
convalesc
addit
strong
inf
respons
gene
typic
induc
inf
like
also
upregul
patient
earli
sarscov
diseas
interestingli
cameron
collabor
present
data
suggest
cytokin
storm
serv
protect
sarscov
patient
progress
uncheck
manner
contribut
develop
inadequ
adapt
immun
respons
sever
diseas
reghunathan
collabor
also
sampl
sar
patient
pbmc
microarray
analysi
find
type
inf
induc
sampl
instead
found
upregul
sever
tissu
inflammationremodel
homeostasi
cellcycl
gene
reghunathan
et
al
compound
fact
reghunathan
discuss
virolog
data
fail
report
stage
sarscov
diseas
sampl
extract
acut
convalesc
etc
sampl
size
n
small
comparison
cameron
et
al
cohort
n
reghunathan
et
al
note
mani
cohort
sar
patient
includ
cameron
cohort
discuss
treat
immunosuppress
corticosteroid
make
result
immunolog
virolog
data
difficult
interpret
evalu
stockman
et
al
sinc
human
clinic
sar
data
complic
host
genet
variat
diseaseexacerb
comorbid
age
variat
variabl
drugtreat
regimen
anim
model
provid
homogen
control
environ
within
ask
question
relat
involv
host
immun
respons
sarscov
infect
nonhuman
primat
nhp
cynomolgu
macaqu
infect
sarscov
haagman
et
al
demonstr
prophylact
administr
pegyl
infa
control
viru
replic
lessen
diseas
patholog
haagman
et
al
concordantli
transcript
profil
nhpinfect
lung
tissu
suggest
infa
b
l
g
also
gene
upregul
sarscovinfect
nhp
de
lang
et
al
sinc
nhp
succumb
infect
propos
inflammatori
respons
viru
infect
describ
aid
control
clearanc
acut
infect
develop
mous
model
recapitul
compon
human
diseas
invalu
viral
pathogenesi
research
young
balbc
strain
mice
support
sar
urbani
replic
lung
infect
caus
lung
patholog
similar
seen
human
case
model
lack
morbid
mortal
sever
lung
patholog
note
human
patient
rockx
et
al
sinc
replic
model
provid
littl
util
regard
diseas
pathogenesi
sever
model
sever
sarscov
diseas
develop
laboratori
creat
molecular
clone
introduct
six
mouseadapt
amino
acid
chang
infect
clone
sar
urbani
icsar
fig
administ
intranas
young
adult
balbc
mice
week
caus
signific
weight
loss
start
weight
result
sever
acut
infect
lung
result
almost
mortal
dpi
mortal
ensu
rapidli
increas
age
balbc
mice
yearold
mice
succumb
infect
begin
dpi
unpublish
observ
sheahan
baric
similarli
rockx
et
al
develop
agerel
mous
model
sever
sarscov
diseas
infect
old
balbc
mice
sarscov
bear
civet
earli
human
glycoprotein
gene
caus
uniform
mortal
dpi
lung
patholog
quit
similar
seen
human
case
due
acut
sever
natur
infect
within
lethal
model
mortal
dpi
mani
aspect
natur
sarscov
infect
develop
adapt
immun
respons
death
viru
clearanc
due
immunopatholog
develop
pulmonari
fibrosi
assess
sinc
major
human
sarscov
case
result
patient
morbid
surviv
model
morbid
without
mortal
develop
order
studi
mechan
host
protect
reflect
prevail
cours
sarscov
diseas
though
current
anim
model
abl
assess
import
adapt
immun
sarscov
pathogenesi
multipl
studi
implic
import
innat
respons
viral
clearanc
glass
et
al
demonstr
sarscov
clear
similar
kinet
wt
mice
strain
lack
b
nk
cell
suggest
innat
immun
respons
alon
suffici
viral
clearanc
glass
et
al
like
gene
express
data
human
sampl
upregul
lung
sarscov
infect
mice
suggest
role
chemokin
protect
glass
et
al
support
glass
et
al
hogan
et
al
demonstr
key
modul
inf
ab
l
g
signal
requir
resolut
sar
infect
implic
import
innat
respons
clearanc
sarscov
hogan
et
al
induct
inf
mice
seem
depend
mous
strain
balbc
mice
induc
type
inf
follow
sarscov
infect
measur
microarray
rockx
et
al
elisa
induct
inf
undetect
mice
robert
et
al
recent
develop
mous
model
acut
sarscov
pathogenesi
signific
morbid
loss
bodi
weight
complet
recoveri
due
activ
innat
respons
recruit
inflammatori
leukocyt
lung
see
sect
immunolog
patholog
discrep
mous
strain
unfortun
caveat
anim
model
viral
diseas
moreov
anim
model
sarscov
pathogenesi
date
fulli
recapitul
innat
adapt
immunopatholog
aspect
sarscov
diseas
nevertheless
mous
model
sarscov
pathogenesi
faith
recapitul
mani
aspect
acut
human
diseas
like
viru
replic
induct
inflammatori
cytokin
migrat
immun
cell
pulmonari
tissu
virusand
immunecellmedi
lung
patholog
weight
loss
also
unlik
human
nhp
vivo
model
transgen
knock
mice
provid
opportun
evalu
role
singl
gene
viral
pathogenesi
recent
novel
panel
genet
dissimilar
recombin
inbr
mice
develop
call
collabor
cross
allow
elucid
genet
pathway
involv
multigen
complex
trait
churchil
et
al
genet
divers
within
collabor
cross
similar
present
human
popul
use
statist
genom
analysi
gene
respons
observ
phenotyp
elucid
rather
evalu
role
singl
gene
sarscov
pathogenesi
knock
mice
use
collabor
cross
sarscov
pathogenesi
may
uncov
role
multipl
host
gene
involv
progress
prevent
diseas
perhap
simplifi
model
within
studi
sarscov
pathogenesi
vitro
model
though
vitro
model
less
complic
vivo
model
result
data
relev
sarscov
pathogenesi
hotli
debat
seem
incongru
vivo
human
primat
mous
data
induct
inf
observ
vitro
infect
variou
primari
immort
interferoncompet
cell
type
fail
induc
produc
inf
vitro
experi
complic
notion
sever
viral
gene
implic
activ
inf
antagonist
kopeckybromberg
et
al
zust
et
al
vitro
data
regard
sarscov
innat
immun
activ
review
infect
interferoncompet
primari
human
airway
epitheli
cell
hae
sarscov
result
induct
secret
inf
result
secret
inflammatori
chemokin
sim
unpublish
data
patholog
evalu
lung
tissu
lethal
sarscov
vitro
data
suggest
airway
epitheli
cell
primari
target
sarscov
infect
yet
induc
inf
vitro
tse
et
al
ye
et
al
nhp
studi
haagman
colleagu
demonstr
epitheli
cell
adjac
infect
epitheli
cell
stain
posit
infb
suggest
possibl
bystand
activ
effect
may
viral
inf
antagonist
suppress
antiviralsens
network
infect
cell
eventu
neighbor
cell
activ
circul
interferon
releas
nonpermiss
cell
sens
viral
protein
genom
rna
releas
extracellular
milieu
result
viralinduc
cell
lysi
sever
studi
focus
infect
profession
antigenpres
cell
like
dendrit
cell
macrophag
also
produc
controversi
data
studi
util
human
pbmcderiv
macrophag
dc
cell
isol
differenti
presenc
cytokin
gmcsf
dc
gmcsf
vitro
cell
popul
resembl
macrophag
dendrit
cell
cell
surfac
stain
profil
frieman
et
al
law
et
al
sarscov
ad
dc
popul
product
infect
ensu
inf
induc
sever
inflammatori
cytokin
induc
secret
frieman
et
al
law
et
al
possibl
explan
dispar
vitro
vivo
data
regard
inf
induct
sarscov
infect
present
cervantesbarragan
colleagu
show
key
differ
convent
cdc
plasmacytoid
dendrit
cell
pdc
popul
respons
sarscov
infect
pdc
differ
cdc
surfac
characterist
cdc
pdc
function
pdc
major
sourc
infa
human
mice
asselinpaturel
et
al
cella
et
al
cervantesbarragan
et
al
siegal
et
al
unlik
investig
artifici
differenti
dc
precursor
cell
isol
pbmc
cervantesbarragan
colleagu
isol
cdc
pdc
popul
directli
human
blood
subsequ
incub
sarscov
demonstr
unlik
cdc
pdc
induc
infb
transcript
produc
larg
amount
infa
protein
cell
media
cervant
assess
pdc
cdc
popul
side
side
cervantesbarragan
provid
possibl
explan
previou
studi
sarscov
infect
dendrit
cell
fail
induc
inf
especi
sinc
differenti
protocol
use
law
tseng
cheung
result
differenti
cdclike
cell
cervant
cheung
et
al
law
et
al
tseng
et
al
cervantesbarragan
also
util
vitro
differenti
mous
cdc
pdc
use
mous
hepat
viru
mhv
experi
interestingli
cytokin
use
cervantesbarragan
gener
cdc
gmcsf
cell
use
investig
creat
though
gener
pdc
use
employ
either
law
tseng
cheung
cervantesbarragan
et
al
cheung
et
al
law
et
al
tseng
et
al
though
work
cervantesbarragan
help
clarifi
discrep
seen
studi
innat
immun
respons
sarscov
bodi
work
defici
demonstr
gener
infecti
viru
infect
cdc
suggest
mechan
sarscov
bind
entri
sinc
express
cdc
address
cervant
cheung
et
al
law
et
al
tseng
et
al
note
studi
demonstr
lectin
dcsignlsign
coreceptor
sarscov
dock
entri
receptor
often
found
dc
apc
jeffer
et
al
nevertheless
interest
see
whether
futur
mousenhp
studi
definit
demonstr
role
pdc
sarscov
pathogenesi
tolllik
receptor
tlr
nodlik
receptor
nlr
exampl
host
cell
protein
recogn
pathogenassoci
molecular
pattern
pamp
oneil
bowi
uehara
et
al
import
adaptor
protein
requir
perpetu
almost
tlr
proinflammatori
signal
well
receptor
signal
event
oneil
bowi
recent
data
implic
progress
prevent
viral
diseas
infect
mice
respiratori
syncyti
viru
rsv
vesicular
stomat
viru
vsv
result
exacerb
diseas
infect
reoviru
result
similar
clinic
cours
seen
wt
mice
johansson
et
al
phipp
et
al
rudd
et
al
zhou
et
al
recent
develop
mous
model
sarscov
pathogenesi
recapitul
aspect
acut
human
infect
wildtyp
mice
infect
pfu
recombin
mous
adapt
sarscov
experi
signific
transient
weight
loss
dpi
high
titer
viru
replic
pfug
dpi
inflamm
lung
induct
proinflammatori
chemokin
cytokin
mark
recruit
inflammatori
monocyt
infect
lung
viru
clearanc
recoveri
diseas
dpi
fig
interestingli
infect
ageand
sexmatch
mice
result
failur
control
viru
replic
significantli
higher
lung
titer
time
delay
induct
inflammatori
gene
transcript
delay
inflammatori
leukocyt
recruit
mortal
dpi
receptor
provid
protect
signal
remain
elucid
though
rule
data
suggest
induct
innat
proinflammatori
chemokin
cytokin
subsequ
recruit
inflammatori
leukocyt
requir
protect
fig
phenotyp
differ
mouseadapt
sarscov
infect
wt
mice
defici
gene
import
adapt
protein
almost
tolllik
receptor
proinflammatori
signal
event
mice
defici
far
suscept
infect
sarscovinduc
mortal
futur
studi
may
elucid
precis
interact
viru
host
respons
protect
signal
furthermor
futur
genet
epidemiolog
studi
sarscovinfect
person
may
reveal
role
gene
polymorph
sarscov
diseas
cellular
receptor
sarscov
infect
angiotensin
convert
enzym
serv
prime
exampl
cellular
protein
strictli
requir
viru
gain
entri
host
cell
also
serv
import
function
host
physiolog
perhap
viral
pathogenesi
diseas
within
year
discov
sarscov
identifi
chief
viru
receptor
util
gain
entri
host
cell
though
attach
factor
also
propos
jeffer
et
al
li
et
al
second
human
coronaviru
also
use
receptor
dock
entri
pyrc
et
al
isol
vitro
express
molecul
variou
speci
mous
civet
human
also
help
elucid
import
facet
epidem
zoonot
sarscov
interact
viru
host
rang
expans
evolut
epidem
strain
express
within
lung
epithelia
type
iii
pneumocyt
primari
cellular
target
sarscov
well
within
intestin
epithelium
vascular
endothelium
heart
kidney
testi
donoghu
et
al
ham
et
al
angiotensin
convert
enzym
ace
key
regul
reninangiotensin
system
ra
help
control
cardiovascular
function
maintain
bodi
blood
pressur
electrolyt
balanc
fig
kuba
et
al
nichol
et
al
ace
metalloproteas
differ
vasoact
peptid
substrat
specif
result
dispar
antagonist
role
maintain
physiolog
homeostasi
kuba
et
al
ace
cleav
peptid
ang
ang
ii
vasoconstrict
effect
induc
hypertens
also
induc
cell
prolifer
fibrosi
kuba
et
al
turner
hooper
contrast
process
ang
ang
process
ang
ii
peptid
ang
act
vasodil
also
antiprolif
apoptot
donoghu
et
al
kuba
et
al
tipni
et
al
vicker
et
al
current
vitro
data
suggest
ang
ii
ligat
signal
angiotensin
receptor
result
product
proimflammatori
cytokin
tnfa
etc
fibrosi
cell
prolifer
mcallisterluca
et
al
vivo
model
liver
fibrosi
ali
support
vitro
data
suggest
ang
ii
exacerb
patholog
patholog
amelior
signal
acid
aspir
model
aliard
imai
et
al
demonstr
protect
mice
injuri
ace
ang
ii
promot
diseas
patholog
similarli
herath
et
al
demonstr
ang
counteract
detriment
effect
ang
ii
liver
diseas
rat
herath
et
al
data
suggest
dualiti
ra
contribut
homeostasi
immunopatholog
perhap
interest
facet
sarscov
relationship
resid
possibl
effect
viru
infect
local
pulmonari
disrupt
ra
homeostasi
fig
within
mous
model
sarscov
replic
kuba
et
al
demonstr
sarscov
infect
diminish
level
within
lung
recombin
sarscov
protein
deliv
sarscov
receptor
angiotensin
convert
enzym
viru
entri
pathogenesi
angiotensin
convert
enzym
ace
key
regul
reninangiotensin
system
ra
help
control
cardiovascular
function
maintain
bodi
blood
pressur
electrolyt
balanc
current
vitro
data
suggest
ang
ii
ligat
signal
angiotensin
receptor
result
product
proimflammatori
cytokin
tnfa
etc
fibrosi
cell
prolifer
b
infect
lung
sarscov
disrupt
ra
homeostasi
current
data
suggest
sarscov
infect
sar
protein
decreas
level
within
lung
therebi
remov
key
regul
processor
proinflammatori
ang
ii
peptid
whose
excess
contribut
sever
diseas
intraperiton
similarli
reduc
level
within
lung
furthermor
within
acid
aspir
model
acut
lung
injuri
ali
administr
sar
recombin
protein
exacerb
ali
measur
chang
lung
elast
accumul
edema
within
h
period
post
acid
injuri
propos
sarscov
sar
decreas
level
within
lung
therebi
remov
key
regul
processor
proinflammatori
ang
ii
peptid
whose
excess
contribut
sever
diseas
proinflammatori
signal
recent
data
haga
et
al
suggest
mechan
downregul
lung
result
increas
lung
tissu
damag
found
cleavag
ectodomain
cell
surfac
mediat
sarscov
tnfa
convert
enzym
cytoplasm
tail
simultan
trigger
product
tissuedestroy
cytokin
tnfa
haga
et
al
taken
togeth
data
provid
interest
insight
possibl
ra
involv
sarscov
pathogenesi
progress
ali
ard
seen
sever
case
sarscov
kuba
et
al
model
acid
aspirationinduc
ali
acut
injuri
assess
within
h
window
compar
virusinduc
lung
injuri
phenotyp
evolv
mani
hour
day
acid
aspir
model
exist
outsid
context
viru
infect
induct
innat
adapt
immun
respons
found
contribut
consider
sarscov
pathogenesi
human
recent
transgen
mous
creat
express
target
epitheli
cell
via
promot
mccray
et
al
although
promot
target
express
lung
epithelium
mice
also
express
larg
amount
central
nervou
system
cn
epithelia
infect
mice
epidem
strain
sar
urbani
result
mortal
like
due
replic
infect
within
cn
sinc
cn
manifest
chief
patholog
observ
human
sarscov
infect
data
suggest
transgen
mice
control
nonlung
cellspecif
promot
may
limit
determin
pathway
sarscov
pathogenesi
within
host
although
mice
like
succumb
infect
cn
increas
amount
pulmonari
protect
lung
patholog
predict
model
present
kuba
et
al
sinc
transgen
mice
extrem
suscept
sarscov
infect
may
use
highli
stringent
model
assess
vaccin
efficaci
challeng
futur
given
interest
conflict
data
regard
ra
sarscov
pathogenesi
futur
evalu
within
current
anim
model
sarscov
pathogenesi
may
help
resolv
discrep
interest
see
sarscov
infect
aceor
mice
modul
develop
sever
sarscov
diseas
use
commerci
avail
drug
block
telmisartan
ace
context
sarscov
infect
may
also
provid
interest
inform
involv
ra
system
sarscov
pathogenesi
lastli
uncoupl
physiolog
function
sarscov
receptor
function
gener
catalyt
inact
knock
mice
would
allow
sarscov
infect
cleavag
angii
could
occur
one
would
predict
infect
catalyt
inact
mice
would
experi
sever
diseas
due
absenc
protect
metabol
proinflammatori
angii
clear
vaccin
passiv
immun
technolog
among
import
public
health
intervent
past
year
contribut
complet
erad
smallpox
marasco
sui
plotkin
though
vaccin
campaign
erad
polio
measl
develop
nation
diseas
vaccineprevent
diseas
continu
plagu
develop
nation
rapidli
newli
emerg
infecti
diseas
like
sarscov
provid
unpredict
scenario
field
vaccinolog
diseas
never
seen
human
popul
aris
spread
rapidli
reagent
necessari
vaccin
develop
yet
exist
emerg
virus
aris
zoonot
pool
especi
problemat
vaccin
therapeut
target
previous
evolv
strain
might
function
strain
associ
contemporari
outbreak
diseas
seen
sarscov
epidem
isol
viru
allow
rapid
gener
kill
dna
viral
vector
vaccin
within
year
start
epidem
sui
et
al
tang
et
al
given
sequenc
divers
bat
sarscov
reservoir
like
kill
vaccin
fail
newli
emerg
strain
aris
futur
especi
sinc
antisera
direct
bat
glycoprotein
neutral
human
epidem
strain
becker
et
al
like
vaccin
practic
passiv
immun
prevent
infect
curtail
establish
diseas
first
shown
robert
koch
late
demonstr
sheep
antisera
diptheria
toxin
could
protect
death
human
marasco
sui
recent
technolog
like
phage
display
memori
b
cell
immort
develop
produc
suffici
quantiti
human
monoclon
antibodi
humab
direct
specif
viral
antigen
marasco
sui
technolog
allow
rapid
develop
neutral
humab
direct
sarscov
within
year
begin
epidem
sui
et
al
discuss
problem
associ
sarscov
vaccin
passiv
immun
therapi
fall
three
categori
includ
sarscov
antigen
variat
therapi
efficaci
b
complic
immunosenesc
sarscov
vaccin
efficaci
c
sarscov
vaccin
immunopotenti
lung
patholog
within
human
infect
sarscov
multipl
antigen
target
adapt
immun
respons
although
cell
respons
direct
nonstructur
replicas
protein
measur
convalesc
patient
major
b
cell
respons
direct
structur
protein
qiu
et
al
yang
et
al
studi
explor
cell
respons
sarscov
patient
li
et
al
frequent
target
peptid
resid
within
orf
protein
lesser
respons
e
n
protein
studi
evalu
humor
respons
sar
antigen
patient
sampl
antibodi
respons
orf
n
measur
antibodi
target
protein
capabl
neutral
qiu
et
al
studi
demonstr
antibodi
direct
glycoprotein
capabl
neutral
sarscov
although
conflict
data
regard
antibodi
neutral
also
report
akerstrom
et
al
cameron
et
al
qiu
et
al
yount
et
al
bodi
work
relat
sarscov
vaccin
develop
astound
unfortun
mani
studi
evalu
immun
respons
antigen
fail
evalu
vaccin
efficaci
sarscov
viru
challeng
bai
et
al
jin
et
al
liu
et
al
zhang
et
al
inactiv
whole
viru
vector
sarscov
vaccin
trial
number
differ
anim
model
demonstr
sarscov
spike
glycoprotein
critic
compon
protect
immun
passiv
transfer
sarscov
sspecif
sera
suffici
provid
protect
infect
diseas
caus
homolog
sarscov
strain
buchholz
et
al
deme
et
al
et
al
kapadia
et
al
qin
et
al
spruth
et
al
subbarao
et
al
wang
et
al
yang
et
al
zhou
et
al
zhou
et
al
howev
current
anim
model
univers
display
acut
sarscovlik
diseas
vaccin
evalu
context
viru
replic
without
sever
acut
lung
injuri
chu
et
al
deme
et
al
haagman
et
al
haagman
osterhau
robert
et
al
subbarao
robert
model
may
underrepres
import
cellmedi
humor
respons
control
prolong
infect
pathogenesi
seen
human
case
sarscov
fact
develop
sarscov
anim
model
recapitul
acut
prolong
infect
develop
adapt
immun
would
greatli
benefit
studi
sarscov
pathogenesi
sarscov
vaccin
develop
nevertheless
sever
replic
mouseadapt
lethal
agerel
model
acut
sarscov
pathogenesi
exist
current
effect
system
within
assess
vaccin
passiv
immun
efficaci
deme
et
al
robert
et
al
robert
et
al
robert
et
al
rockx
et
al
effect
human
monoclon
antibodi
humab
util
prophylact
acut
treatment
viral
infect
marasco
sui
sinc
gener
effect
vaccin
vaccineinduc
immun
timeconsum
product
broadli
neutral
humab
target
emerg
viral
diseas
may
valuabl
use
healthcar
worker
vulner
popul
emerg
viral
outbreak
situat
immunolog
popul
past
emerg
sarscov
zoonot
pool
continu
circul
sarslik
virus
within
bat
popul
provid
perfect
situat
develop
humab
therapi
protect
futur
emerg
due
unknown
antigen
ident
futur
emerg
sarscov
present
difficult
problem
crossneutr
epitop
target
passiv
immun
therapi
order
effect
treat
futur
emerg
sarscov
vaccin
success
humab
passiv
immun
sarscov
broadli
neutral
current
futur
sarscov
strain
one
first
humab
develop
sarscov
effect
neutral
pseudovirusbear
epidem
civet
protein
effect
pseudoviru
bear
civetlik
vitro
sui
et
al
use
humab
zhu
et
al
report
complet
neutral
sar
urbani
sarscov
bear
less
effect
neutral
sarscov
bear
log
reduct
viru
lung
titer
compar
control
humab
passiv
transfer
experi
young
balbc
mice
contrast
antibodi
zhu
et
al
also
report
complet
protect
viru
replic
day
post
infect
sar
urbani
use
similar
dose
humab
rockx
et
al
also
demonstr
crossreact
potent
neutral
abil
humab
passiv
transfer
studi
mice
effect
neutral
sar
urbani
recombin
sarscov
bear
earli
epidem
phase
though
slightli
less
efficaci
recombin
sarscov
bear
civet
glycoprotein
log
reduct
viru
lung
titer
day
post
infect
compar
control
ab
though
protect
viru
replic
mice
antibodi
protect
urbani
mice
clinic
sign
diseas
death
data
highlight
import
use
one
strain
sarscov
evalu
sarscov
therapi
sinc
humab
discuss
provid
vari
degre
protect
replic
depend
sarscov
variant
employ
vitro
vivo
assay
also
data
suggest
complet
abrog
replic
may
necessari
protect
clinic
sign
sarscov
diseas
importantli
escap
mutant
gener
humab
significantli
attenu
mice
sinc
epidem
strain
may
longer
exist
natur
vaccin
epidem
strain
antigen
follow
challeng
epidem
strain
may
biolog
medic
relev
design
due
complic
design
vaccin
futur
emerg
sarscov
whose
antigen
ident
unknown
sever
difficult
question
aris
develop
effect
sarscov
therapi
sarscov
antigen
pool
antigen
provid
greatest
degre
crossprotect
vaccin
prevent
diseas
futur
emerg
sarscov
vaccin
formul
effect
elderli
lastli
sarscov
strain
employ
challeng
viru
assess
vaccin
efficaci
begin
answer
question
within
current
anim
model
sarscov
pathogenesi
sever
anim
model
see
sect
common
vaccin
formul
util
sarscov
vaccin
develop
data
summar
tabl
major
approach
sarscov
vaccin
platform
develop
includ
whole
kill
recombin
viral
vector
dna
liveattenu
sarscov
recombin
protein
subunit
vaccin
bisht
et
al
bisht
et
al
chen
et
al
czub
et
al
darnel
et
al
deme
et
al
du
et
al
du
et
al
du
et
al
faber
et
al
gai
et
al
et
al
jin
et
al
kapadia
et
al
kapadia
et
al
kobing
et
al
lamirand
et
al
linig
et
al
martin
et
al
qin
et
al
qu
et
al
see
et
al
see
et
al
spruth
et
al
tsunetsuguyokota
et
al
wang
et
al
weingartl
et
al
yang
et
al
zhang
et
al
zhou
et
al
zhu
et
al
ideal
anim
model
use
assess
protect
vaccin
efficaci
would
display
viru
replic
patholog
morbid
mortal
though
model
util
assess
vaccin
efficaci
demonstr
viru
replic
lung
manifest
diseas
demonstr
virusinduc
morbid
sever
lung
patholog
none
demonstr
mortal
tabl
turn
stringent
anim
model
mouseadapt
sarscov
transgen
mice
etc
demonstr
morbid
mortal
current
avail
need
employ
order
provid
thorough
evalu
vaccin
protect
efficaci
moreov
vaccin
studi
assess
protect
vaccin
efficaci
sarscov
viru
challeng
without
util
success
vaccin
remain
unknown
furthermor
sinc
futur
sarscov
emerg
like
differ
antigen
ident
compar
epidem
strain
sar
urbani
vaccin
challeng
strain
ideal
antigen
distinct
vaccin
antigen
thu
allow
import
assess
vaccin
crossprotect
knowledg
two
sarscov
vaccin
studi
date
assess
protect
efficaci
use
heterolog
challeng
viru
deme
et
al
lamirand
et
al
success
vaccin
age
popul
necessari
goal
sarscov
vaccin
platform
unfortun
one
studi
date
focus
develop
effect
vaccin
vulner
popul
deme
et
al
conundrum
discuss
mention
immunosenesc
occur
age
hamper
innat
adapt
immun
respons
whose
collabor
necessari
effici
vaccin
sarscov
epidem
particularli
harsh
age
popul
mortal
rang
peopl
age
booth
et
al
leung
et
al
liang
et
al
peiri
et
al
sarscovlik
viru
reemerg
futur
would
imper
current
vaccin
strategi
success
vulner
popul
unfortun
success
vaccin
elderli
popul
difficult
unpredict
task
due
immunosenesc
bernstein
et
al
bernstein
et
al
eaton
et
al
effro
goodwin
et
al
goronzi
et
al
gruver
et
al
hayn
swain
pawelec
larbi
vallejo
vasto
et
al
much
research
relat
vaccin
immunosenesc
perform
influenza
current
model
predict
influenza
vaccin
efficaci
elderli
popul
rang
vaccin
young
adult
effect
discrep
seem
result
senesc
immun
system
malfunct
multipl
level
goodwin
et
al
defect
antigen
present
cell
activ
cytokin
secret
affect
gener
effect
adapt
immun
system
helper
helper
th
cell
effector
b
cell
cytotox
cell
cell
result
diminish
vaccin
efficaci
effro
fujihashi
et
al
goodwin
et
al
goronzi
et
al
hayn
swain
mcelhaney
et
al
vallejo
wang
et
al
current
research
suggest
defect
senesc
immun
system
overcom
administr
cytokin
adjuv
cpg
dna
vaccin
effect
activ
apcsth
cell
therebi
increas
probabl
gener
appropri
effector
cell
requir
success
vaccin
hayn
et
al
higgin
et
al
pulendran
ahm
thompson
et
al
sinc
influenza
west
nile
viru
sarscov
infect
produc
disproportion
diseas
elderli
develop
success
vaccin
strategi
elderli
broad
public
health
applic
anonym
leung
et
al
murray
et
al
sarscovinfect
age
human
infect
age
mice
sar
urbani
result
sever
diseas
compar
similar
infect
young
adult
mice
senesc
mice
viru
replic
lung
patholog
enhanc
viru
eventu
clear
suggest
compon
age
immun
system
less
effect
control
viru
replic
though
senesc
mous
model
fulli
recapitul
sarscov
acut
extend
cellmedi
pathogenesi
seen
human
serv
use
model
studi
effect
immunosenesc
vaccin
efficaci
deme
et
al
demonstr
venezuelan
equin
enceph
viru
replicon
particl
express
sar
urbani
vrp
vaccin
provid
complet
protect
replic
sarscov
bear
zoonot
heterolog
protect
variabl
senesc
mice
deme
et
al
due
lack
signific
morbid
mortal
sarscov
replic
model
previou
vaccin
studi
unabl
assess
protect
diseas
death
could
specul
diminish
viru
replic
would
diminish
diseas
nevertheless
heterogen
antigen
challeng
viru
provid
stringent
thorough
biolog
medic
relev
model
within
assess
vaccin
efficaci
therefor
employ
antigen
divers
panel
sarscov
antigen
vaccin
coupl
use
similarli
divers
lethal
challeng
viru
panel
may
repres
pertin
relev
strategi
assess
vaccin
efficaci
fig
moreov
robust
newli
develop
lethal
balbc
model
would
allow
assess
vaccin
induc
protect
replic
also
diseas
mortal
use
vsv
vector
express
urbani
rvsv
vogel
et
al
obtain
similar
result
age
mice
neutral
titer
vaccin
age
mice
low
provid
protect
replic
upon
homolog
sar
urbani
challeng
similar
situat
observ
human
data
suggest
vaccin
young
mice
induc
robust
crossprotect
igg
respons
igg
respons
age
anim
depress
magnitud
crossreact
compar
young
anim
data
indic
age
mice
reduc
neutral
titer
homolog
virus
reduc
titer
close
relat
heterolog
virus
deme
et
al
underli
mechan
vaccin
failur
elderli
evolv
major
focu
futur
sarscov
vaccin
research
effect
vaccin
induc
specif
protect
immun
confer
protect
futur
diseas
unfortun
vaccin
sometim
exacerb
diseas
upon
natur
infect
pathogen
vaccin
design
protect
phenomenon
vaccineinduc
immun
patholog
often
call
immunopotenti
diseas
werl
et
al
measl
mv
rsv
paramyxoviru
respiratori
pathogen
caus
signific
morbid
mortal
infant
might
prevent
develop
effect
vaccin
polack
et
al
varga
et
al
two
infam
exampl
immunopotenti
diseas
surfac
formalininactiv
mv
fimv
rsv
firsv
vaccin
polack
et
al
varga
et
al
infant
prior
exposur
rsv
vaccin
firsv
vaccin
develop
virusspecif
antibodi
protect
subsequ
natur
rsv
infect
durbin
durbin
fact
firsvvaccin
children
infect
rsv
suffer
enhanc
rsv
diseas
requir
hospit
children
die
infect
durbin
durbin
patholog
hallmark
firsv
immunopotenti
lung
peripher
eosinophilia
rare
seen
natur
cours
rsv
infect
durbin
durbin
varga
et
al
similar
firsv
protect
immun
wane
infant
shortli
vaccin
fimv
subsequ
natur
measl
infect
result
sever
diseas
eosinophilia
uncharacterist
natur
measl
infect
polack
et
al
due
sever
vaccineassoci
diseas
complic
vaccin
withdrawn
research
effort
focus
elucid
underli
molecular
mechan
vaccineinduc
patholog
within
mous
nonhuman
primat
anim
model
firsv
fimv
found
induc
atyp
adapt
immun
respons
seen
natur
infect
de
swart
et
al
durbin
durbin
polack
et
al
varga
et
al
effect
respons
gener
firsv
fimv
differ
firsv
vaccin
induc
allerg
immun
respons
cell
secret
cytokin
upregul
product
potent
eosinophil
chemotact
molecul
eotaxin
de
swart
et
al
durbin
durbin
varga
et
al
natur
infect
vaccin
individu
thought
exacerb
atyp
allerg
immun
respons
lung
de
swart
et
al
durbin
durbin
varga
et
al
interestingli
similar
result
achiev
macaqu
use
formalininactiv
human
metapneumoviru
vaccin
fihmpv
follow
hmpv
challeng
de
swart
et
al
fimv
vaccin
nonhuman
primat
model
suggest
associ
allerg
respons
gener
mv
challeng
recruit
eosinophil
site
viru
replic
diseas
patholog
part
mediat
immun
complex
deposit
polack
et
al
vaccineinduc
immunopotenti
also
observ
coronaviru
vaccinia
viru
vector
felin
infecti
periton
viru
fipv
vaccin
vennema
et
al
observ
vaccin
recombin
vaccinia
viru
express
fipv
vf
induc
shortliv
immun
kitten
vennema
et
al
challeng
vfsimmun
anim
suffer
much
sever
diseas
receiv
control
vaccin
vf
vaccineinduc
immunopotenti
suspect
result
antibodydepend
enhanc
ade
viru
infect
subneutr
antibodi
coat
fipv
virion
allow
entri
product
infect
cell
eg
macrophag
normal
target
natur
infect
vaccineinduc
immunopotenti
diseas
also
shown
vector
vaccin
express
sarscov
n
protein
deme
et
al
demonstr
mice
vaccin
vrpbase
vaccin
express
sarscov
n
gene
protect
infect
develop
enhanc
lung
immunopatholog
upon
challeng
eosinophilia
seen
control
mice
data
recent
confirm
yasui
et
al
deme
et
al
yasui
et
al
data
suggest
n
protein
fail
provid
protect
diseas
acut
replic
model
also
promot
enhanc
diseas
pathogenesi
lung
evalu
sever
formalininactiv
sarscov
vaccin
suggest
vaccin
primarili
induc
respons
natur
sarscov
infect
human
induc
primarili
respons
spruth
et
al
tsunetsuguyokota
et
al
wong
et
al
given
data
firsv
fimv
vaccin
alter
natur
th
respons
induc
sever
diseas
upon
challeng
caution
use
develop
vector
vaccin
contain
sarscov
n
formalininactiv
sarscov
vaccin
may
promot
rather
prevent
diseas
support
viewpoint
shown
kill
sar
vaccin
presenc
absenc
alum
induc
extens
lung
patholog
especi
lung
age
anim
inocul
heterolog
lethal
challeng
virus
deme
et
al
prepar
due
everincreas
human
popul
increas
wildlif
habitat
destruct
human
inhabit
demand
exot
anim
food
inabl
human
control
success
track
zoonot
diseas
wild
anim
popul
emerg
novel
viral
pathogen
zoonot
pool
continu
threaten
human
global
public
health
develop
antivir
therapi
viral
pathogen
might
emerg
futur
difficult
multifacet
problem
critic
improv
global
health
sarscov
first
signific
emerg
viru
twentyfirst
centuri
avail
revers
genet
timeord
sequenc
variat
anim
human
strain
robust
avail
biochem
reagent
agerel
anim
model
provid
uniqu
opportun
studi
mani
basic
aspect
novel
viru
emerg
antigen
divers
pathogenesi
antivir
therapi
develop
vaccin
immunopotenti
diseas
sarscov
vaccin
must
provid
broad
protect
larger
zoonot
pool
success
vaccin
strategi
may
provid
templat
develop
broadli
reactiv
vaccin
emerg
virus
like
filovirus
nipah
viru
avian
influenza
virus
importantli
sarscov
pathogenesi
exacerb
immunosenesc
popul
suffer
disproportion
diseas
burden
emerg
virus
use
age
model
sarscov
pathogenesi
vaccin
efficaci
immunolog
defici
age
immun
system
andor
variabl
requir
success
vaccin
may
elucid
data
may
appli
improv
vaccin
viral
pathogen
caus
disproportion
diseas
burden
vulner
popul
like
elderli
west
nile
viru
influenza
noroviru
sarscov
rsv
etc
past
use
whole
kill
vaccin
vaccin
success
prevent
diseas
also
contribut
immunopotenti
diseas
mechan
exacerb
diseas
complet
understood
uncov
mechan
sarscov
nucleocapsidinduc
immunopotenti
may
reveal
common
host
pathway
vaccin
formul
eg
firsv
fimv
mediat
vaccinerel
patholog
altern
uniqu
genet
differ
coronavirus
paramyxovirus
may
reveal
entir
new
pathway
virushost
interact
potenti
vaccineinduc
immun
patholog
thu
current
model
sarscov
pathogenesi
employ
studi
mani
difficult
problem
associ
develop
effect
therapi
emerg
pathogen
futur
studi
may
provid
solut
prepar
us
futur
sarscov
emerg
emerg
yet
unknown
viral
pathogen
